A Phase II Nonrandomised Open-Label Study of Liposomal Daunorubicin (DaunoXome) in Advanced Soft Tissue Sarcoma

Thirty four patients with advanced soft tissue sarcoma not previously treated with an anthracycline were treated with DaunoXome 100mg/m2 every 3 weeks. Thirty-three patients were evaluable for toxicity. Grade 3-4 neutropenia was seen in 20 patients (60.6%), complicated by febrile neutropenia in 2 (6...

Descripción completa

Detalles Bibliográficos
Autores principales: McTiernan, Anne, Whelan, Jeremy, Leahy, Michael, Woll, Penella J., Judson, Ian
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1510953/
https://www.ncbi.nlm.nih.gov/pubmed/17040090
http://dx.doi.org/10.1155/SRCM/2006/41080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1510953/
https://www.ncbi.nlm.nih.gov/pubmed/17040090
http://dx.doi.org/10.1155/SRCM/2006/41080

Ejemplares similares